BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that it will host an Analyst and Investor Day on Wednesday, July 19, 2017. The event is scheduled to take place from 8:30-11:45 AM Eastern Time in New York City, NY.
The agenda will include an overview of the Company's development and pre-commercial plans for Amikacin Liposome Inhalation Suspension (ALIS), as well as an introduction to the Company's Phase 2 candidate INS1007.
The program will also feature a presentation by Dr. Kevin L. Winthrop, MD, MPH, Professor at the School of Public Health, and Associate Professor in the Departments of Infectious Diseases and Ophthalmology at Oregon Health & Science University.
The event will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be
archived for a period of 90 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung disease caused by MAC in the United States or the European Union. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of
their respective owners.
Laura Perry or Heather Savelle
Source: Insmed Incorporated
News Provided by Acquire Media